Atopic Asthma Clinical Trial
Official title:
Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics
The purpose of this study is to characterize the time course of B cell activation after allergen challenge, and more specifically measure the M1 prime related biomarkers.
M1 prime is a segment of IgE found only in the membrane form of IgE and not on soluble IgE
found in serum. Membrane IgE (and M1prime) is expressed on IgE-switched B cells, IgE-memory
B cels, and IgE-plasmablasts. Depletion of IgE-switched B cells and plasmablasts will reduce
IgE-producing cells and serum IgE, and may be a target for treatment of allergic asthma. A
humanized antibody targeting M1 prime is being developed by Genentech, Inc., as a potential
therapeutic for asthma.
Currently, the efficacy of MEMP1972A is being assessed in an allergen challenge study in
mild asthmatics (MOP4843g). Extensive biomarker samples have been incorporated in that study
to characterize the mechanism of action (MOA) as well as the kinetics of the MOA of
MEMP1972A, which are poorly understood at this time. Furthermore, samples for the B cell
enriched peripheral blood flow cytometry and bone marrow aspirates to evaluate the kinetics
and MOA of MEMP1972a are collected only 24 hr after allergen challenge due to visit and
sample volume limitations. It is known that maximal B cell responses are expected ~7 days
after allergen stimulation. Therefore, the purpose of this research study will be to
characterize the time course of B cell activation after allergen challenge, and more
specifically measure the M1 prime related biomarkers.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01448954 -
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma
|
Phase 2 | |
| Withdrawn |
NCT01049178 -
Randomized Controlled Trial of Silymarin in Asthma
|
Phase 2/Phase 3 | |
| Terminated |
NCT00644514 -
Genetics of Asthma - Bronchoscopy Studies
|
Phase 1 | |
| Completed |
NCT00861211 -
Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects
|
Phase 2 | |
| Completed |
NCT00784459 -
The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics
|
Phase 2 | |
| Terminated |
NCT00671593 -
Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge
|
Phase 1 | |
| Completed |
NCT05098600 -
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
|
||
| Completed |
NCT02758548 -
Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects
|
Phase 2 | |
| Completed |
NCT01179256 -
Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma
|
N/A | |
| Completed |
NCT01545245 -
Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants
|
N/A | |
| Completed |
NCT03603522 -
Probiotics and Capsaicin Evoked Coughs
|
N/A | |
| Completed |
NCT04728711 -
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
|
Phase 2 | |
| Recruiting |
NCT03928431 -
Restoration of Microbiota in Neonates
|
N/A | |
| Completed |
NCT02327234 -
Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma
|
N/A | |
| Completed |
NCT01890161 -
A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma
|
Phase 2 | |
| Completed |
NCT03665701 -
Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites
|
N/A | |
| Completed |
NCT04397081 -
Atopic Diseases & Human Papilloma Virus
|